What To Expect From agilon health’s (AGL) Q3 Earnings

Healthcare services company Agilon Health (NYSE:AGL) will be reporting results this Tuesday after the bell. Here’s what to look for.

agilon health missed analysts’ revenue expectations by 4.8% last quarter, reporting revenues of $1.39 billion, down 5.9% year on year. It was a disappointing quarter for the company, with a significant miss of analysts’ revenue estimates and a significant miss of analysts’ EPS estimates. It added 7,000 customers to reach a total of 498,000.

Is agilon health a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, analysts are expecting agilon health’s revenue to decline 2% year on year to $1.42 billion, a reversal from the 27.6% increase it recorded in the same quarter last year. Adjusted loss is expected to come in at -$0.14 per share.

Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. agilon health has missed Wall Street’s revenue estimates five times over the last two years.

Looking at agilon health’s peers in the outpatient & specialty care segment, some have already reported their Q3 results, giving us a hint as to what we can expect. Select Medical delivered year-on-year revenue growth of 7.2%, beating analysts’ expectations by 2.7%, and Encompass Health reported revenues up 9.4%, in line with consensus estimates. Select Medical traded down 2.7% following the results while Encompass Health was also down 7.1%.

Read our full analysis of Select Medical’s results here and Encompass Health’s results here.

Investors in the outpatient & specialty care segment have had steady hands going into earnings, with share prices flat over the last month. agilon health is down 28.6% during the same time and is heading into earnings with an average analyst price target of $1.23 (compared to the current share price of $0.80).

When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.